Showing 7281-7290 of 9298 results for "".
- Dr. James Del Rosso Presents ‘Medicine Chest’ at Winter Clinical 2026https://practicaldermatology.com/news/dr-james-del-rosso-presents-medicine-chest-at-winter-clinical-2026/2485373/James Q. Del Rosso, DO, delivered his annual “What’s New in the Medicine Chest” update at the 2026 Winter Clinical Dermatology Conference, covering new therapies, novel data, and practice-changing pearls spanning from molluscum and hyperhidrosis to vitiligo, lichen planus, and even mastocytosis.<
- Dr. Darrell Rigel Highlights Urgent Skin Cancer Trends at Winter Clinical 2026https://practicaldermatology.com/news/dr-darrell-rigel-highlights-urgent-skin-cancer-trends-at-winter-clinical-2026/2485361/Skin cancer continues its upward trajectory, with new data showing that one in 19 Americans will be diagnosed with melanoma in their lifetime. This alarming statistic headlined a wide-ranging presentation by Darrell S. Rigel, MD, MS, at the 2026 Winter Clinical Dermatology Conference in Hawaii, w
- Swann Dermatology Partners Merges with Forefront Dermatologyhttps://practicaldermatology.com/news/swann-dermatology-partners-merges-with-forefront-dermatology-in-strategic-expansion-move/2485339/Swann Dermatology Partners (SDP), a multi-location practice based in Springfield, Missouri, announced that it has officially joined Forefront Dermatology, a nationwide dermatology network backed by private equity firm Partners Group.
- Vitiligo Linked to Elevated Risk of Herpes Zoster: Cohort Studyhttps://practicaldermatology.com/news/vitiligo-linked-to-elevated-risk-of-herpes-zoster-study-finds/2485328/A new cohort study from Taiwan indicated vitiligo is independently associated with a heightened risk of herpes zoster (HZ), with systemic immunosuppressive therapies compounding the risk further. Using data from Taiwan's Longit
- Study: Photodynamic Therapy Usage Shifts With Season, Geographyhttps://practicaldermatology.com/news/study-photodynamic-therapy-usage-shifts-with-season-geography/2485308/Seasonal and geographic variation influences the use of photodynamic therapy (PDT) for actinic keratoses (AKs), according to a large cross-sectional study. Reasearchers analyzed over 79 million procedural claims from 2015 to 202
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://practicaldermatology.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a
- Review: Wide Variability in Dermatology ICD Code Validityhttps://practicaldermatology.com/news/review-wide-variability-in-dermatology-icd-code-validity/2485230/A systematic review published in JAMA Dermatology showed wide variability in the accuracy of International Classification of Diseases (ICD) codes used to identify dermatologic conditions in U.S. administrative datasets.
- GLP-1RAs Linked with Reduced Itch Prevalence in Diabetes Cohorthttps://practicaldermatology.com/news/glp-1-receptor-agonists-tied-to-reduced-itch-prevalence-in-diabetes-cohort/2485184/Results from a new retrospective cohort analysis suggest some glucagon-like peptide-1 (GLP-1) receptor agonists are associated with a reduced prevalence of itch the type 2 diabetes mellitus (T2DM), independent of glycemic control.
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res